Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Ricklie Julian
Assistant Professor, Medicine - (Clinical Scholar Track)
Medicine
Full Page
Overview
Research
More
Collaboration
(17)
Denise Roe
Mutual work: 2 Publications
Collaboration Details
Linda Garland
Mutual work: 5 Grants﹒9 Proposals
Collaboration Details
Abhijeet Kumar
Mutual work: 13 Proposals﹒10 Grants
Collaboration Details
Alejandro Recio Boiles
Mutual work: 15 Proposals﹒12 Grants
Collaboration Details
Jennifer Segar
Mutual work: 12 Grants﹒15 Proposals
Collaboration Details
Page 1 of 4
Previous page
Next page
Grants
(28)
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent And Combination Therapy In Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Active
·
2024
·
$0 / $1.6M
·
External
Co-Investigator (COI)
cancer,
pharmacokinetics,
drug therapy,
clinical trial,
tumor treatment
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anti-Cancer Therapies in Solid Tumors
Active
·
2024
·
$0 / $724K
·
External
Co-Investigator (COI)
cancer,
immunotherapy,
clinical trial,
monotherapy,
combination therapy
Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination with Low Dose Radiotherapy in Subjects with Stage 4 Metastatic Non-Small Cell Lung Cancer
Active
·
2024
·
$3.5M / $577.4K
·
External
Principal Investigator (PI)
immunotherapy,
radiotherapy,
cancer,
clinical trial,
metastatic
A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527
Active
·
2024
·
$0 / $348.6K
·
External
Co-Investigator (COI)
oncology,
clinical trials,
immunotherapy,
pharmacology,
drug safety
An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Active
·
2024
·
$1.1M / $275K
·
External
Principal Investigator (PI)
immunotherapy,
clinical trial,
head and neck cancer,
combination therapy,
genetic therapy
Page 1 of 6
Previous page
Next page
Publications
(8)
Recent
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
2023
cancer,
immunotherapy,
clinical trial,
therapeutic antibodies,
targeted therapy
The impact of socioeconomic and geographic factors on access to transoral robotic/endoscopic surgery for early stage oropharyngeal malignancy
2022
socioeconomic factors,
geographic factors,
transoral robotic surgery,
endoscopic surgery,
oropharyngeal malignancy
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
2022
clinical trials,
cancer treatment,
immunotherapy,
head and neck cancer,
drug combination
Immunotherapy Approaches in HPV-Associated Head and Neck Cancer
2021
immunotherapy,
hpv,
head and neck cancer,
cancer treatment,
biomedical research
Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic R/M) head and neck squamous cell carcinoma HNSCC)
2020
cancer,
immunotherapy,
clinical trial,
targeted therapy,
biological drugs
2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer
2019
oncology,
lung cancer,
scientific advances,
thoracic
Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden.
2018
pulmonary carcinoma,
rb1 loss,
slfn11 expression,
tumor mutational burden,
neuroendocrine carcinoma
Tell Me Your Story: A Pilot Narrative Medicine Curriculum During the Medicine Clerkship
2015
narrative medicine,
medical education,
curriculum development,
clinical clerkship,
pilot program
